The FDA approved PI3K inhibitor GDC-0941 enhances in vitro the anti-neoplastic efficacy of Axitinib against c-myc-amplified high-risk medulloblastoma.
about
The FDA approved PI3K inhibitor GDC-0941 enhances in vitro the anti-neoplastic efficacy of Axitinib against c-myc-amplified high-risk medulloblastoma.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh
2018年學術文章
@zh-hant
name
The FDA approved PI3K inhibito ...... ied high-risk medulloblastoma.
@en
The FDA approved PI3K inhibito ...... ied high-risk medulloblastoma.
@nl
type
label
The FDA approved PI3K inhibito ...... ied high-risk medulloblastoma.
@en
The FDA approved PI3K inhibito ...... ied high-risk medulloblastoma.
@nl
prefLabel
The FDA approved PI3K inhibito ...... ied high-risk medulloblastoma.
@en
The FDA approved PI3K inhibito ...... ied high-risk medulloblastoma.
@nl
P2093
P2860
P356
P1476
The FDA approved PI3K inhibito ...... fied high-risk medulloblastoma
@en
P2093
Anna Casati
Dagmar Dilloo
Julia Velz
Martin Olschewski
Michael Ehrhardt
Torsten Pietsch
P2860
P304
P356
10.1111/JCMM.13489
P577
2018-01-29T00:00:00Z